Registry of Endocrine Tumors (Thyroid, Parathyroid, Adrenal, Endocrine Pancreas, Endocrine Digestive Tube)

Registre Tumeurs Endocrine - Eurocrine

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03410394

Acronym

eurocrine

Enrollment

3000

Registered

2018-01-25

Start date

2015-01-01

Completion date

2030-01-01

Last updated

2025-02-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endocrine Tumor

Keywords

adrenal, thyroid, parathyroid, endocrine pancreas, endocrine digestive tube

Brief summary

This registry aims to collect informations about patients with endocrine tumors (Thyroid, Parathyroid, Adrenal, Endocrine Pancreas, Endocrine Digestive Tube) who undergo endocrine surgical procedures. This registry is part of the Eurocrine Project.

Detailed description

The EUROCRINE project aims to decrease morbidity and mortality of rare endocrine tumours, by means of a pan-European database. Recording and accessing data at the European level, makes it possible to identify these tumours, which cannot be distinguished at local or national level, because of their extreme rarity. Dissemination of results aims to raise clinical standards and reduce differences in practise between clinics and member states, and thereby diminish morbidity and mortality. Comparison of practice and outcomes will be especially interesting for centres wanting to improve their standards to what is currently considered best practice. EUROCRINE will be a key means by which the medical profession, researchers, health policy makers, and not least patients, can benefit from an increase in knowledge related to diagnosis, treatment, and future clinical research in the field of rare endocrine tumours.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* patients who undergo surgical procedures for endocrine tumors at the University Nancy Brabois Hospital

Exclusion criteria

* unable to receive clear information * refusal to sign the consent form

Design outcomes

Primary

Measure	Time frame	Description
Postoperative complications (endocrine surgical procedure)	12 months after surgical procedure	morbidity rate in percentage (%)

Secondary

Measure	Time frame	Description
Postoperative mortality (endocrine surgical procedure)	12 months after surgical procedure	mortality rate in percentage (%)
CT imaging before endocrine surgical procedure (Tumor characteristics)	Baseline	Density in Hounsfield unit (HU)
CT imaging before endocrine surgical procedure (Coronary artery score)	Baseline	CAC score in Agatston score unit (HU)
CT imaging before endocrine surgical procedure (Sarcopenia)	preoperative period	Evaluation of sarcopenia using L3 skeletal muscle index (in cm²/m²)
Bone mineral density	Baseline	dual-energy x-ray absorptiometry (DEXA) (in T-score unit)
Intraoperative systolic arterial pressure	Intraoperative	systolic arterial pressure (in mmHg)
Postoperative complications severity (endocrine surgical procedure)	12 months after surgical procedure	Dindo-Clavien classification in percentage (%)
Parathormone plasma levels	Baseline and up to 12 months after surgical procedure	Parathormone (in pg/mL)
Aldosterone plasma levels	Baseline and up to 12 months after surgical procedure	Aldosterone (in pmol/L)
Plasma renin activity	Baseline and up to 12 months after surgical procedure	Renin (in μIU/mL)
Plasma free metanephrines	Baseline and up to 12 months after surgical procedure	metanephrines (in nmol/L)
PET scanning	Baseline	standardized uptake values (SUV tumor / SUV liver ratio)
Intraoperative diastolic arterial pressure	Intraoperative	diastolic arterial pressure (in mmHg)

Countries

France

Contacts

Primary Contactlaurent Brunaud, MD, PhD

l.brunaud@chru-nancy.fr

Backup ContactBrunaud